Co-diagnostics, inc. reports third quarter 2024 financial results

Salt lake city , nov. 7, 2024 /prnewswire/ -- co-diagnostics, inc. (nasdaq: codx), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the quarter ended september 30, 2024. third quarter 2024 financial results: revenue of $0.6 million, which declined from $2.5 million during the prior year primarily due to timing of grant revenue recognition.
CODX Ratings Summary
CODX Quant Ranking